Saltar al contenido
Merck
Todas las fotos(2)

Key Documents

View All Documentation

V900919

Sigma-Aldrich

Anfotericina B from Streptomyces sp.

suitable for cell culture, Vetec™, BioReagent

Sinónimos:

Fungizona

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
C47H73NO17
Número de CAS:
1397-89-3
Peso molecular:
924.08
Beilstein/REAXYS Number:
78342
EC Number:
215-742-2
MDL number:
MFCD00877763
UNSPSC Code:
12352207
PubChem Substance ID:
329830225

product name

Anfotericina B from Streptomyces sp., Vetec™, reagent grade, BioReagent, suitable for cell culture, ~80%

grade

reagent grade

Quality Level

100

product line

BioReagent
Vetec™

assay

~80%

technique(s)

cell culture | mammalian: suitable

antibiotic activity spectrum

fungi
yeast

mode of action

cell membrane | interferes

storage temp.

2-8°C

SMILES string

C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)C[C@H](O)[C@H]3C(O)=O)[C@@H](O)[C@@H](N)[C@@H]1O

InChI

1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1

InChI key

APKFDSVGJQXUKY-INPOYWNPSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

La anfotericina B se une a los esteroles formando poros en la membrana y provocando la salida de moléculas pequeñas. La máxima eficacia del producto es contra hongos y levaduras.
Amphotericin B binds to sterols, forming pores in the membrane, and causing small molecules to leak out. The product is most effective against fungi and yeast.
Amphotericin B is used for primary treatment of acute invasive fungal infections, such as aspergillosis.

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H372

Hazard Classifications

STOT RE 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
White MH, et al.
Clinical Infectious Diseases, 27(2), 296-302 (1998)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, et al.
The New England Journal of Medicine, 347(6), 408-415 (2002)
Malav S Trivedi et al.
The Journal of nutritional biochemistry, 25(10), 1011-1018 (2014-07-16)
Dietary interventions like gluten-free and casein-free diets have been reported to improve intestinal, autoimmune and neurological symptoms in patients with a variety of conditions; however, the underlying mechanism of benefit for such diets remains unclear. Epigenetic programming, including CpG methylation
Chitralekha Mohanty et al.
Anticancer research, 34(6), 2801-2806 (2014-06-13)
The use of ion radiation therapy is growing due to the continuously increasing positive clinical experience obtained. Therefore, there is a high interest in radio-biological experiments comparing the relative efficiency in cell killing of ions and photons as photons are
Daniel D Brown et al.
Breast cancer research and treatment, 153(2), 311-321 (2015-08-19)
Because there are currently no reliable predictors for progression of ductal carcinoma in situ (DCIS) to invasive disease, nearly all patients receive comprehensive therapy, leading to over-treatment in many cases. Few in vitro models for studying DCIS progression have been
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico